Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatostatin for prevention of post-ERCP pancreatitis and quality of life
ChiCTR1900021583Phase 4Recruiting
- Sponsor
- Pingxiang People's Hospital
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) and acute pancreatitis (AP) comparing Somatostatin with Placebo / blank control (2 arms). Primary endpoint: Blood amylase. Started Feb 2019; status: recruiting.
02
Drugs
somatostatin
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)acute pancreatitis (AP)
Beyond the preview
Go deeper on ChiCTR1900021583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021583.